Neutralizing monoclonal antibodies to fight HIV-1 : on the threshold of success

Autores
Jaworski, Juan Pablo; Vendrell, Alejandrina; Chiavenna, Sebastián Matias
Año de publicación
2017
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Anti-human immunodeficiency virus type-1 (anti-HIV-1) neutralizing monoclonal antibodies are broadening the spectrum of pre- and post-exposure treatment against HIV-1. A better understanding of how these antibodies develop and interact with particular regions of the viral envelope protein is guiding a more rational structure-based immunogen design. The aim of this article is to review the most recent advances in the field, from the development of these particular antibodies during natural HIV-1 infection, to their role preventing infection, boosting endogenous immune responses and clearing both free viral particles and persistently infected cells.
Inst.de Virología
Fil: Jaworski, Juan Pablo. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Vendrell, Alejandrina. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina
Fil: Chiavenna, Sebastián Matias. Ferrer Advanced Biotherapeutics, Ferrer Internacional; España
Fuente
Frontiers in immunology 7 : 661 (March 2017)
Materia
Virus de la Inmunodeficiencia Humana
Anticuerpos Monoclonales
Profilaxis de las Enfermedades
Human Immunodeficiency Virus
Monoclonal Antibodies
Disease Prophylaxis
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
INTA Digital (INTA)
Institución
Instituto Nacional de Tecnología Agropecuaria
OAI Identificador
oai:localhost:20.500.12123/2005
Acceder
id INTADig_7abe223cdfbaa53d3f26f88d72152e27
oai_identifier_str oai:localhost:20.500.12123/2005
network_acronym_str INTADig
repository_id_str l
network_name_str INTA Digital (INTA)
spelling Neutralizing monoclonal antibodies to fight HIV-1 : on the threshold of successJaworski, Juan PabloVendrell, AlejandrinaChiavenna, Sebastián MatiasVirus de la Inmunodeficiencia HumanaAnticuerpos MonoclonalesProfilaxis de las EnfermedadesHuman Immunodeficiency VirusMonoclonal AntibodiesDisease ProphylaxisAnti-human immunodeficiency virus type-1 (anti-HIV-1) neutralizing monoclonal antibodies are broadening the spectrum of pre- and post-exposure treatment against HIV-1. A better understanding of how these antibodies develop and interact with particular regions of the viral envelope protein is guiding a more rational structure-based immunogen design. The aim of this article is to review the most recent advances in the field, from the development of these particular antibodies during natural HIV-1 infection, to their role preventing infection, boosting endogenous immune responses and clearing both free viral particles and persistently infected cells.Inst.de VirologíaFil: Jaworski, Juan Pablo. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Vendrell, Alejandrina. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; ArgentinaFil: Chiavenna, Sebastián Matias. Ferrer Advanced Biotherapeutics, Ferrer Internacional; España2018-03-09T14:28:17Z2018-03-09T14:28:17Z2017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://hdl.handle.net/20.500.12123/20051664-3224https://doi.org/10.3389/fimmu.2016.00661https://www.frontiersin.org/articles/10.3389/fimmu.2016.00661/fullFrontiers in immunology 7 : 661 (March 2017)reponame:INTA Digital (INTA)instname:Instituto Nacional de Tecnología Agropecuariaenginfo:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-sa/4.0/Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)2025-09-29T13:44:15Zoai:localhost:20.500.12123/2005instacron:INTAInstitucionalhttp://repositorio.inta.gob.ar/Organismo científico-tecnológicoNo correspondehttp://repositorio.inta.gob.ar/oai/requesttripaldi.nicolas@inta.gob.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:l2025-09-29 13:44:15.89INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuariafalse
dc.title.none.fl_str_mv Neutralizing monoclonal antibodies to fight HIV-1 : on the threshold of success
title Neutralizing monoclonal antibodies to fight HIV-1 : on the threshold of success
spellingShingle Neutralizing monoclonal antibodies to fight HIV-1 : on the threshold of success
Jaworski, Juan Pablo
Virus de la Inmunodeficiencia Humana
Anticuerpos Monoclonales
Profilaxis de las Enfermedades
Human Immunodeficiency Virus
Monoclonal Antibodies
Disease Prophylaxis
title_short Neutralizing monoclonal antibodies to fight HIV-1 : on the threshold of success
title_full Neutralizing monoclonal antibodies to fight HIV-1 : on the threshold of success
title_fullStr Neutralizing monoclonal antibodies to fight HIV-1 : on the threshold of success
title_full_unstemmed Neutralizing monoclonal antibodies to fight HIV-1 : on the threshold of success
title_sort Neutralizing monoclonal antibodies to fight HIV-1 : on the threshold of success
dc.creator.none.fl_str_mv Jaworski, Juan Pablo
Vendrell, Alejandrina
Chiavenna, Sebastián Matias
author Jaworski, Juan Pablo
author_facet Jaworski, Juan Pablo
Vendrell, Alejandrina
Chiavenna, Sebastián Matias
author_role author
author2 Vendrell, Alejandrina
Chiavenna, Sebastián Matias
author2_role author
author
dc.subject.none.fl_str_mv Virus de la Inmunodeficiencia Humana
Anticuerpos Monoclonales
Profilaxis de las Enfermedades
Human Immunodeficiency Virus
Monoclonal Antibodies
Disease Prophylaxis
topic Virus de la Inmunodeficiencia Humana
Anticuerpos Monoclonales
Profilaxis de las Enfermedades
Human Immunodeficiency Virus
Monoclonal Antibodies
Disease Prophylaxis
dc.description.none.fl_txt_mv Anti-human immunodeficiency virus type-1 (anti-HIV-1) neutralizing monoclonal antibodies are broadening the spectrum of pre- and post-exposure treatment against HIV-1. A better understanding of how these antibodies develop and interact with particular regions of the viral envelope protein is guiding a more rational structure-based immunogen design. The aim of this article is to review the most recent advances in the field, from the development of these particular antibodies during natural HIV-1 infection, to their role preventing infection, boosting endogenous immune responses and clearing both free viral particles and persistently infected cells.
Inst.de Virología
Fil: Jaworski, Juan Pablo. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Vendrell, Alejandrina. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina
Fil: Chiavenna, Sebastián Matias. Ferrer Advanced Biotherapeutics, Ferrer Internacional; España
description Anti-human immunodeficiency virus type-1 (anti-HIV-1) neutralizing monoclonal antibodies are broadening the spectrum of pre- and post-exposure treatment against HIV-1. A better understanding of how these antibodies develop and interact with particular regions of the viral envelope protein is guiding a more rational structure-based immunogen design. The aim of this article is to review the most recent advances in the field, from the development of these particular antibodies during natural HIV-1 infection, to their role preventing infection, boosting endogenous immune responses and clearing both free viral particles and persistently infected cells.
publishDate 2017
dc.date.none.fl_str_mv 2017
2018-03-09T14:28:17Z
2018-03-09T14:28:17Z
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12123/2005
1664-3224
https://doi.org/10.3389/fimmu.2016.00661
https://www.frontiersin.org/articles/10.3389/fimmu.2016.00661/full
url http://hdl.handle.net/20.500.12123/2005
https://doi.org/10.3389/fimmu.2016.00661
https://www.frontiersin.org/articles/10.3389/fimmu.2016.00661/full
identifier_str_mv 1664-3224
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv Frontiers in immunology 7 : 661 (March 2017)
reponame:INTA Digital (INTA)
instname:Instituto Nacional de Tecnología Agropecuaria
reponame_str INTA Digital (INTA)
collection INTA Digital (INTA)
instname_str Instituto Nacional de Tecnología Agropecuaria
repository.name.fl_str_mv INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuaria
repository.mail.fl_str_mv tripaldi.nicolas@inta.gob.ar
_version_ 1844619120272736256
score 12.558318

Publicaciones similares